drugset / Trial / NCT00979563
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of OratecanTM. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to standard therapy or for which no established therapy exists at the time of study participation.
Timeline
- Start
- 2008-07
- Primary completion
- 2010-03
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK | Unknown | 60 mg | Oral |
| Subject | Irinotecan | Small molecule | 2 mg | Oral |
| Subject | Irinotecan | Small molecule | 5 mg | Oral |
| Subject | Irinotecan | Small molecule | 20 mg | Oral |